This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PDI Is Optimistic on Outlook

Biopharmaceutical marketing company PDI (PDII - Get Report) said Wednesday that it expects full-year earnings to top analysts' predictions.

The company expects to earn 75 cents to 80 cents a share, up from its previous estimate of 48 cents to 53 cents a share. The estimate excludes settlement expenses from earlier in the year. The company cited new business awarded to its contract sales unit and expectations of a solid performance from its hypertension drug Lotensin.

Analysts currently expect earnings of 47 cents a share. The company lost 62 cents a share in 2002.

The company also announced that GlaxoSmithKline (GSK) awarded it a contract that could mean $80 million to $85 million in revenue in the period from July 2003 through September 2004. The total revenue impact is about $30 million in 2003, the company said.

PDI will release second-quarter results on Aug. 5 after the market closes. Analysts expect the company to earn a penny a share. Shares of Upper Saddle River, N.J.-based PDI closed at $10.93 Wednesday on the Nasdaq.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
PDII $2.12 -0.47%
AAPL $118.44 -2.36%
FB $94.14 0.14%
GOOG $631.28 0.91%
TSLA $259.66 -2.40%

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs